OpenAI acquires Orchestra Bio to expand drug development tools
OpenAI says it has acquired Orchestra Bio, a platform that helps biopharma teams coordinate drug development. OpenAI plans to combine Orchestra's team and technology with Rosalind, its AI models and tools for life sciences research. Orchestra's platform lets people and AI agents work together to monitor studies and track drug programs, and OpenAI says the goal is to help scientists bring treatments to patients sooner.